Medical policy: Biofeedback as a Treatment of Chronic Pain; (Formerly Biofeedback and Neurofeedback Therapy)

Policy number: MP 2.064

Clinical benefit

  • Minimize safety risk or concern.
  • Minimize harmful or ineffective interventions.
  • Assure appropriate level of care.
  • Assure appropriate duration of service for interventions.
  • Assure that recommended medical prerequisites have been met.
  • Assure appropriate site of treatment or service.

Effective date: 9/1/2026

Policy

Biofeedback may be considered medically necessary for chronic back and neck pain.

Biofeedback may be considered medically necessary for the treatment of cancer-related pain.

Biofeedback as a treatment of chronic pain in all other situations is investigational. There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure for the above indications.

Cross-reference:

  • MP 1.033 Sacral Nerve Neuromodulation-Stimulation
  • MP 2.029 Neurofeedback
  • MP 2.062 Temporomandibular Disorder
  • MP 2.096 Electromyography (EMG) (Needle and Non-Needle) of the Anal or Urethral Sphincter
  • MP 2.304 Medical Treatments of Autism Spectrum Disorders
  • MP 2.398 Biofeedback as a Treatment of Fecal Incontinence or Constipation
  • MP 2.399 Biofeedback as a Treatment of Urinary Incontinence in Adults
  • MP 2.400 Biofeedback as a Treatment of Headache
  • MP 2.401 Biofeedback for Miscellaneous Indications
  • MP 4.012 Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
  • MP 6.020 Transcutaneous Electrical Nerve Stimulation and Transcutaneous Afferent Patterned Stimulation

Product variations

This policy is only applicable to certain programs and products administered by Capital Blue Cross and subject to benefit variations. Please see additional information below.

FEP PPO - Refer to FEP Medical Policy Manual. The FEP Medical Policy Manual can be found at: FEP Medical Policy Manual.

Description/Background

Biofeedback as a Treatment of Chronic Pain

Biofeedback is intended to teach individuals self-regulation of certain physiologic processes not normally considered to be under voluntary control. The various forms of biofeedback mainly differ in the nature of the disease or disorder under treatment, the biologic variable that the subject attempts to control, and the information that is fed back to the subject.

Biofeedback techniques include peripheral skin temperature feedback, blood-volume-pulse feedback (vasoconstriction and dilation), vasoconstriction training (temporalis artery), and electromyographic biofeedback; they may be used alone or in conjunction with other therapies (e.g., relaxation, behavioral management, medication). Biofeedback training is done either in individual or group sessions. A typical program consists of 10 to 20 training sessions of 30 minutes each.

Biofeedback has been proposed as a treatment for a variety of diseases and disorders, including anxiety, headaches, hypertension, movement disorders, incontinence, pain, asthma, Raynaud disease, and insomnia.

Treatment for chronic pain is often multimodal and typically includes psychological therapy. Psychological techniques vary but may include cognitive therapy, which teaches subjects the ability to cope with stressful stimuli by attempting to alter negative thought patterns and dysfunctional attitudes, and behavioral approaches to reduce muscle tension and break the pain cycle. Relaxation, using any of a variety of techniques including meditation or mental imagery, is considered a behavioral therapy that may be used alone or as a component of a cognitive-behavioral therapy (CBT) program. Electromyography (EMG) biofeedback has also been used for the treatment of chronic pain, on the assumption that the ability to reduce muscle tension will be improved through feedback of data to the patient regarding degree of muscle tension. While some consider EMG biofeedback to be a method to obtain relaxation, others consider biofeedback to be distinct from other relaxation techniques.

Regulatory Status

A variety of biofeedback devices have been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process. These devices are designated by the FDA as class II with special controls and are exempt from premarket notification requirements. The FDA defines a biofeedback device as “an instrument that provides a visual or auditory signal corresponding to the status of 1 or more of a patient’s physiological parameters (e.g., brain alpha wave activity, muscle activity, skin temperature, etc.) so that the patient can control voluntarily these physiological parameters.”

Evidence pertaining to the use of biofeedback for urinary incontinence is addressed in evidence review in MP 2.399.

Evidence pertaining to the use of biofeedback for headaches is addressed in evidence review in MP 2.400.

Evidence pertaining to the use of biofeedback for miscellaneous indications (treatment of hypertension, anxiety, asthma, movement disorders [e.g, motor function after stroke, injury, or lower-limb surgery], and other applications) is addressed in evidence review in MP 2.401.

Evidence pertaining to the use of biofeedback for fecal incontinence or constipation is addressed in evidence review in MP 2.398.

Rationale

Summary of evidence

Biofeedback as a Treatment of Back Pain and Cancer Pain

For individuals who have chronic pain who receive biofeedback, the evidence includes multiple RCTs for different pain syndromes. Relevant outcomes are symptoms, functional outcomes, quality of life, and medication use. In a meta-analysis on the efficacy of biofeedback for chronic back pain, Sielski and colleagues (2017) evaluated 21 studies (n=1062). They found a significant small to medium effect size for pain intensity reduction (Hedges’ g=0.60; 95% CI, 0.44 to 0.76) that was stable with a significant small-to-large effect size (Hedges’ g=0.62; 95% CI, 0.40 to 0.84) over an average of 8-months follow-up. The researchers also found improvement in depression, disability, muscle tension, and coping. They concluded that biofeedback improved short and long-term pain-related outcomes for chronic back pain. In a clinical practice guideline on treatments for back pain (Qaseem, 2017), the ACP recommends that clinicians should initially prescribe nonpharmacologic treatment for chronic low back pain, including electromyography biofeedback (Grade: strong recommendation).

In their guidelines on adult cancer pain (V.2.2025), the National Comprehensive Cancer Network (NCCN) recommends biofeedback as an evidence-based treatment modality in reference to referral to mental health consultation (2A recommendation).

Biofeedback as a Treatment of Chronic Pain

For individuals who have chronic pain who receive biofeedback, the evidence includes multiple randomized controlled trials (RCTs) for different pain syndromes. Relevant outcomes are symptoms, functional outcomes, quality of life, and medication use. The results of these RCTs, some of which were sham-controlled, did not consistently report a benefit for biofeedback. Some RCTs reported improved outcomes with biofeedback, but these improvements were often of uncertain clinical significance or were not durable. Many other RCTs have found that biofeedback did not provide a significantly greater benefit in outcomes when it was used instead of or in addition to other conservative interventions such as exercise. Overall, the available RCTs were limited by small sample sizes and high dropout rates. This evidence base does not permit conclusions about the specific effects of biofeedback beyond the nonspecific effects of sham interventions, nor does it permit conclusions about the contribution of biofeedback beyond that of other conservative treatments for pain. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Definitions

Electromyogram (EMG): is the graphic record of resting and voluntary muscle activities as a result of electrical stimulation.

Physiologic: pertains to normal functions of the human body as opposed to pathological.

Disclaimer

Capital Blue Cross’ medical policies are used to determine coverage for specific medical technologies, procedures, equipment, and services. These medical policies do not constitute medical advice and are subject to change as permitted by law or applicable clinical evidence from independent treatment guidelines. Treating providers are solely responsible for medical advice and treatment of members. These polices are not a guarantee of coverage or payment. Payment of claims is subject to a determination regarding the member’s benefit program and eligibility on the date of service, and a determination that the services are medically necessary and appropriate. Final processing of a claim is based upon the terms of contract that applies to the members’ benefit program, including benefit limitations and exclusions. If a provider or a member has a question concerning this medical policy, please contact Capital Blue Cross’ Provider Services or Member Services.

Coding information

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

Covered when medically necessary:

Procedure Codes

90875*

90876*

90901

 

 

*Covered when both psychotherapy & biofeedback are provided

ICD-10-CM diagnosis codes
Description

G89.3

Neoplasm related pain (acute) (chronic)

M54.2

Cervicalgia

M54.5

Low back pain

M54.50

Low back pain, unspecified

M54.51

Vertebrogenic low back pain

M54.59

Other low back pain

References

  1. Food and Drug Administration. Biofeedback device. 21 CFR - 882.5050 (1998). Accessed September 22, 2025.
  2. U.S. Department of Health and Human Services. Pain management best practices. May 2019. Accessed September 26, 2025.
  3. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. Jan 2005; 113(1-2): 9-19. PMID 15621359
  4. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. Feb 2008; 9(2): 105-21. PMID 18055266
  5. Calderone A, Mazzurco Masi VM, De Luca R, et al. The impact of biofeedback in enhancing chronic pain rehabilitation: A systematic review of mechanisms and outcomes. Heliyon. Jan 30 2025; 11(2): e41917. PMID 39897804
  6. Williams ACC, Fisher E, Hearn L, et al. Psychological therapies for the management of chronic pain (excluding headache) in adults. Cochrane Database Syst Rev. Aug 12 2020; 8(8): CD007407. PMID 32794606
  7. Fisher E, Law E, Dudeney J, et al. Psychological therapies for the management of chronic and recurrent pain in children and adolescents. Cochrane Database Syst Rev. Sep 29 2018; 9(9): CD003968. PMID 30270423
  8. Humphreys PA, Gevirtz RN. Treatment of recurrent abdominal pain: components analysis of four treatment protocols. J Pediatr Gastroenterol Nutr. Jul 2000; 31(1): 47-51. PMID 10896070
  9. Palermo TM, Eccleston C, Lewandowski AS, et al. Randomized controlled trials of psychological therapies for management of chronic pain in children and adolescents: an updated meta-analytic review. Pain. Mar 2010; 148(3): 387-397. PMID 19910118
  10. Henschke N, Ostelo RW, van Tulder MW, et al. Behavioural treatment for chronic low-back pain. Cochrane Database Syst Rev. Jul 07 2010; 2010(7): CD002014. PMID 20614428
  11. Yeldan I, Canan GD, Akcın IB. Biofeedback Sensor vs. Physiotherapist Feedback During Core Stabilization Training in Patients with Chronic Nonspecific Low Back Pain. Appl Psychophysiol Biofeedback. Mar 2024; 49(1): 103-113. PMID 37878122
  12. Kapitza KP, Passie T, Bernateck M, et al. First non-contingent respiratory biofeedback placebo versus contingent biofeedback in patients with chronic low back pain: a randomized, controlled, double-blind trial. Appl Psychophysiol Biofeedback. Sep 2010; 35(3): 207-17. PMID 20237953
  13. Lazariou A, Paschali M, Vlismark ES, et al. Biofeedback EMG alternative therapy for chronic low back pain (the BEAT-pain study). Digit Health. 2023; 9: 20552076231154386. PMID 36776410
  14. Tan G, Rintala DH, Jensen MP, et al. A randomized controlled trial of hypnosis compared with biofeedback for adults with chronic low back pain. Eur J Pain. Feb 2015; 19(2): 271-80. PMID 24934738
  15. Glombiewski JA, Hartwich-Tersek J, Rief W. Two psychological interventions are effective in severely disabled, chronic back pain patients: a randomised controlled trial. Int J Behav Med. Jun 2010; 17(2): 97-107. PMID 19967572
  16. Ananiás J, Vidal C, Ortiz-Muñoz L, et al. Use of electromyographic biofeedback in rehabilitation following anterior cruciate ligament reconstruction: a systematic review and meta-analysis. Physiotherapy. Jun 2024; 123: 19-29. PMID 38244487
  17. Karaborklu Argut S, Celik D, Yasacı Z. Effectiveness of therapeutic electromyographic biofeedback after orthopedic knee surgeries: a systematic review. Disabil Rehabil. Jul 2022; 44(14): 3364-3372. PMID 33417500
  18. Collins NJ, Bisset LM, Crossley KM, et al. Efficacy of nonsurgical interventions for anterior knee pain: systematic review and meta-analysis of randomized trials. Sports Med. Jan 01 2012; 42(1): 31-49. PMID 22149696
  19. Campo M, Zadro JR, Pappas E, et al. The effectiveness of biofeedback for improving pain, disability and work ability in adults with neck pain: A systematic review and meta-analysis. Musculoskelet Sci Pract. Apr 2021; 52: 102317. PMID 33461043
  20. Kamonseki DH, Calixte LB, Barreto RPG, et al. Effects of electromyographic biofeedback interventions for shoulder pain and function: Systematic review and meta-analysis. Clin Rehabil. Jul 2021; 35(7): 952-963. PMID 33517777
  21. Juul-Kristensen B, Larsen CM, Eshoj H, et al. Positive effects of neuromuscular shoulder exercises with or without EMG-biofeedback, on pain and function in participants with subacromial pain syndrome - A randomised controlled trial. J Electromyogr Kinesiol. Oct 2019; 48: 161-168. PMID 31394380
  22. Kosterink SM, Huis in 't Veld RM, Cagnie B, et al. The clinical effectiveness of a myofeedback-based teletreatment service in patients with non-specific neck and shoulder pain: a randomized controlled trial. J Telemed Telecare. 2010; 16(6): 316-21. PMID 20798425
  23. Ma C, Szeto GP, Yan T, et al. Comparing biofeedback with active exercise and passive treatment for the management of work-related neck and shoulder pain: a randomized controlled trial. Arch Phys Med Rehabil. Jun 2011; 92(6): 849-58. PMID 21621660
  24. Middaugh S, Thomas KJ, Smith AR, et al. EMG Biofeedback and Exercise for Treatment of Cervical and Shoulder Pain in Individuals with a Spinal Cord Injury: A Pilot Study. Top Spinal Cord Inj Rehabil. 2013; 19(4): 311-23. PMID 24244096
  25. Sandsjö L, Larsman P, Huis in 't Veld RM, et al. Clinical evaluation of a myofeedback-based teletreatment service applied in the workplace: a randomized controlled trial. J Telemed Telecare. 2010; 16(6): 329-35. PMID 20798427
  26. Arami J, Rezasoltani A, Khalkhali Z, et al. The effect of two exercise therapy programs (proprioceptive and endurance training) to treat patients with chronic non-specific neck pain. JBUMS. 2012;14(1):77-84.
  27. Bisset A, Mitchell KR, Major G. The cervico-brachial pain syndrome: muscle activity and pain relief. Behav Change. 1985;2(2):129-132.
  28. Bobos P, Billiş E, Paparizolou DT, et al. Does Deep Cervical Flexor Muscle Training Affect Pain Pressure Thresholds of Myofascial Trigger Points in Patients with Chronic Neck Pain? A Prospective Randomized Controlled Trial. Rehabil Res Pract. 2016; 2016: 6480826. PMID 27990302
  29. Delive L, Ahlström L, Jönsson A, et al. Myofeedback training and intensive muscular strength training to decrease pain and improve work ability among female workers on long-term sick leave with neck pain: a randomized controlled trial. Int Arch Occup Environ Health. Mar 2011; 84(3): 335-46. PMID 20803028
  30. Ehrenborg C, Archenholtz B. Is surface EMG biofeedback an effective training method for persons with neck and shoulder complaints after whiplash-associated disorders concerning activities of daily living and pain -- a randomized controlled trial. Clin Rehabil. Aug 2010; 24(8): 715-26. PMID 20562165
  31. Eslamian F, Jahanjoo F, Dolatkhah N, et al. Relative Effectiveness of Electroacupuncture and Biofeedback in the Treatment of Neck and Upper Back Myofascial Pain: A Randomized Clinical Trial. Arch Phys Med Rehabil. May 2020; 101(5): 770-780. PMID 31954696
  32. Iqbal ZA, Rajan R, Khan SA, et al. Effect of deep cervical flexor muscles training using pressure biofeedback on pain and disability of school teachers with neck pain. J Phys Ther Sci. Jun 2013; 25(6): 657-61. PMID 24259822
  33. Jull G, Trott P, Potter H, et al. A randomized controlled trial of exercise and manipulative therapy for cervicogenic headache. Spine (Phila Pa 1976). Sep 01 2002; 27(17): 1835-43; discussion 1843. PMID 12221344
  34. Jull G, Falla D, Treleaven J, et al. Retraining cervical joint position sense: the effect of two exercise regimes. J Orthop Res. Mar 2007; 25(3): 404-12. PMID 17143898
  35. Nezamuddin M, Answer S, Khan SA, et al. Efficacy of pressure-biofeedback guided deep cervical flexor training on neck pain and muscle performance in visual display terminal operators. J Musculoskelet Res. 2013;16(3):1350011
  36. Voerman GE, Sandsjö L, Vollenbroek-Hutten MM, et al. Effects of ambulant myofeedback training and ergonomic counselling in female computer workers with work-related neck-shoulder complaints: a randomized controlled trial. J Occup Rehabil. Mar 2007; 17(1): 137-52. PMID 17260162
  37. Wani S, Rana N, Jethwa J, et al. Comparative efficacy of cervical retraction exercises (McKenzie) with and without using pressure biofeedback in cervical spondylosis. Int J Ther Rehabil. 2013;20(10):501-508.
  38. de Oliveira AKA, da Costa KSA, de Lucena GL, et al. Comparing exercises with and without electromyographic biofeedback in subacromial pain syndrome: A randomized controlled trial. Clin Biomech (Bristol). Mar 2022; 93: 105596. PMID 35183878
  39. Ribeiro D, Silva AG. A single session of visual feedback improves range of motion in patients with chronic idiopathic neck pain: A randomized and controlled study. Musculoskeletal Care. Mar 2019; 17(1): 72-78. PMID 30378756
  40. Aggarwal VR, Lovie K, Peters S, et al. Psychosocial interventions for the management of chronic orofacial pain. Cochrane Database Syst Rev. Nov 09 2011; (11): CD008456. PMID 22071849
  41. McNeely ML, Olivo SA, Magee DJ. A systematic review of the effectiveness of physical therapy interventions for temporomandibular disorders. Phys Ther. May 2006; 86(5): 710-25. PMID 16649894
  42. Medlicott MS, Harris SR. A systematic review of the effectiveness of exercise, manual therapy, electrotherapy, relaxation training, and biofeedback in the management of temporomandibular disorder. Phys Ther. Jul 2006; 86(7): 955-73. PMID 16813476
  43. Weydert JA, Ball TM, Davis MF. Systematic review of treatments for recurrent abdominal pain. Pediatrics. Jan 2003; 111(1): e1-11. PMID 12509588
  44. Glombiewski JA, Bernardy K, Häuser W. Efficacy of EMG- and EEG-Biofeedback in Fibromyalgia Syndrome: A Meta-Analysis and a Systematic Review of Randomized Controlled Trials. Evid Based Complement Alternat Med. 2013; 2013: 962741. PMID 24082911
  45. Babu AS, Mathew E, Danda D, et al. Management of patients with fibromyalgia using biofeedback: a randomized control trial. Indian J Med Sci. Aug 2007; 61(8): 455-61. PMID 17679735
  46. van Santen M, Bolwijn P, Verstappen F, et al. A randomized clinical trial comparing fitness and biofeedback training versus basic treatment in patients with fibromyalgia. J Rheumatol. Mar 2002; 29(3): 575-81. PMID 11908576
  47. Buckelew SP, Conway R, Parker J, et al. Biofeedback/relaxation training and exercise interventions for fibromyalgia: a prospective trial. Arthritis Care Res. Jun 1998; 11(3): 196-209. PMID 9782811
  48. Macfarlane GJ, Paudyal P, Doherty M, et al. A systematic review of evidence for the effectiveness of practitioner-based complementary and alternative therapies in the management of rheumatic diseases: osteoarthritis. Rheumatology (Oxford). Dec 2012; 51(12): 2224-33. PMID 22923762
  49. Yilmaz OO, Senocak O, Sahin E, et al. Efficacy of EMG-biofeedback in knee osteoarthritis. Rheumatol Int. May 2010; 30(7): 887-92. PMID 19693508
  50. Durmuş D, Alayli G, Cantürk F. Effects of quadriceps electrical stimulation program on clinical parameters in the patients with knee osteoarthritis. Clin Rheumatol. May 2007; 26(5): 674-8. PMID 16897119
  51. Greco CM, Rudy TE, Manusis E. Effects of a stress-reduction program on psychological function, pain, and physical function in systemic lupus erythematosus patients: a randomized controlled trial. Arthritis Rheum. Aug 15 2004; 51(4): 625-34. PMID 15334437
  52. Bergeron S, Binik YM, Khalifé S, et al. A randomized comparison of group cognitive-behavioral therapy, surface electromyographic biofeedback, and vestibulectomy in the treatment of dyspareunia resulting from vulvar vestibulitis. Pain. Apr 2001; 91(3): 297-306. PMID 11275387
  53. Hegmann KT, Travis R, Andersson GBJ, et al. Non-Invasive and Minimally Invasive Management of Low Back Disorders. J Occup Environ Med. Mar 2020; 62(3): e111-e138. PMID 31977923
  54. Benzon HT, Connis RT, De Leon-Casasola OA, et al. Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. Anesthesiology. Apr 2010; 112(4): 810-33. PMID 20124882
  55. Kreiner DS, Matz P, Bono CM, et al. Guideline summary review: an evidence-based clinical guideline for the diagnosis and treatment of low back pain. Spine J. Jul 2020; 20(7): 998-1024. PMID 32333996
  56. VA/DoD Clinical Practice Guideline. (2022). The Diagnosis and Treatment of Low Back Pain. Washington, DC: U.S. Government Printing Office. Version 3.0. Accessed September 26, 2025.
  57. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Biofeedback Therapy (30.1). n.d.; Accessed September 26, 2025.
  58. Agency for Healthcare Research and Quality. Systematic Review Update - Noninvasive Nonpharmacologic Treatment for Chronic Pain.
  59. American Society of Anesthesiologists Task Force on Chronic Pain Management, American Society of Regional Anesthesia and Pain Medicine. Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. Anesthesiology. Apr 2010; 112(4): 810-833. PMID 20124882
  60. Eccleston C, Palermo TM, Williams AC, et al. Psychological therapies for the management of chronic and recurrent pain in children and adolescents. Cochrane Database Syst Rev. Apr 15 2009(2):CD003968. PMID 19370592
  61. Eccleston C, Williams AC, Morley S. Psychological therapies for the management of chronic pain (excluding headache) in adults. Cochrane Database Syst Rev. Apr 15 2009(2):CD007407. PMID 19370688
  62. Gatchel RJ, Robinson RC, Pulliam C, et al. Biofeedback with pain patients: evidence for its effectiveness. Seminars in Pain Medicine. June 2003;1(2):55-66.
  63. Pagé I, Marchand AA, Nougarou F, et al. Neuromechanical responses after biofeedback training in participants with chronic low back pain: an experimental cohort study. J Manipulative Physiol Ther. 2015 Sep;38(7):449-57. PMID 26413899
  64. Qaseem A, Wilt TJ, McLean RM, et al. Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American college of physicians. Ann Intern Med. 2017; 166(7):514-530. PMID 28192789
  65. Sella GE, Moss D. Chronic muscle pain, biofeedback, and the neurophysiology of pain. Biofeedback. Spring 2016; 44(1):19-23.
  66. Sielski R, Rief W, Glombiewski JA. Efficacy of biofeedback in chronic back pain: a meta-analysis. Int J Behav Med. 2017; 24(1):25-41. PMID 27307013
  67. Thomas DA, Maslin B, Leyer A, et al. Role of alternative therapies for chronic pain syndromes. Curr Pain Headache Rep. 2016 May;20(5):29. PMID 27038968
  68. Wald A, Bharucha AE, Cosman BC, Whitehead WE. ACG clinical guideline: management of benign anorectal disorders. Am J Gastroenterol. 2014;109(8):1141-1058. doi: 10.1038/ajg.2014.190
  69. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Adult Cancer Pain. 2.2025. May 21, 2025.
  70. Sheinfeld Gorin S, Krebs P, Badr H, et al. Meta-analysis of psychosocial interventions to reduce pain in patients with cancer. J Clin Oncol. 2012; 30(5):530-547. PMID 22253460

Policy history

MP 2.064

06/19/2020 Consensus Review. No changes to policy statement. Product Variation updated. FEP statement updated. Coding reviewed with no changes. References reviewed and updated.

04/27/2021 Minor Review. Deleted number of sessions for tension type headache as the COC addresses number of sessions. Added chronic proctalgia, fecal incontinence in adults with some preserved voluntary urinary sphincter contraction, and non-neurogenic dysfunctional voiding in children as MN indications. Deleted policy guidelines. Updated rationale and references. Added diagnosis codes K59.4; R15.0-R15.9; F98.0; and N39.8 for the new indications.

05/12/2021: Per discussion at preconcept, changing stance from INV to “not medically necessary” for other types of constipation in adults and children.

09/07/2021 Administrative Update. New code G44.86, M54.50-51, and M54.59 added. Effective 10/01/2021.

02/02/2022 Consensus Review. No policy statement changes. References, background, and rationale updated. G44.86 removed.

09/07/2023 Consensus Review. No policy statement changes. Updated references. New ICD10 codes.

10/18/2024 Consensus Review. No change to policy statement. Updated references.

12/18/2025 Minor Review. Policy separated. Policy stances for back, neck, and cancer pain remain on this policy. Added stance for the use of biofeedback for all other situations of chronic pain as INV. Title change. Indications for chronic proctalgia and for treatment of non-neurogenic dysfunctional voiding in children were removed. Indications and coding for fecal incontinence and constipation moved to MP 2.398, urinary incontinence moved to MP 2.399, headache moved to MP 2.400, miscellaneous indications moved to MP 2.401, and neurofeedback moved to MP 2.029. Cross-references, policy guidelines, background, rationale, CPT and ICD-10 coding, and references updated. E0746 moved to MP 2.399, MP 2.400, MP 2.401.